The European Parliament's ITRE Committee session on January 15, 2026, saw a series of intense exchanges mainly between Commissioner Mechthild Woersdoerfer (DG ENER), Kerstin Jorna (DG GROW), and various Members of the European Parliament (MEPs), focusing on the EU's energy infrastructure projects, automotive sector regulation, and biotechnology competitiveness.
The heaviest clash emerged over the legitimacy and criteria for the second list of Projects of Common Interest (PCI) and Projects of Mutual Interest (PMI) under the TEN-E Regulation. Green MEP Marie Toussaint and the Patriots for Europe’s Pascale Piera challenged the Commission's centralized project selection approach and the inclusion of hydrogen projects with questionable sustainability. Woersdoerfer defended the list, emphasizing the EU-added value of cross-border infrastructure projects like hydrogen and CO₂ networks and the inclusion of only green or low-carbon hydrogen. This cleavage reflects an underlying debate over increasing versus limiting EU regulatory power and integration, with Greens/EFA and PfE advocating stronger national sovereignty and environmental safeguards, while the Commission promotes a centralized infrastructure strategy with ambitious cross-border coordination.
The same meeting in Brussels also unpacked the automotive sector's future, where DG GROW's Kerstin Jorna introduced the Automotive Omnibus regulatory simplification tool and the €1.5 billion Battery Booster facility to accelerate production ramp-up. Several MEPs, including renewables proponents and traditionalists, expressed concerns about the Battery Booster’s sufficiency and the risk of raising electric vehicle (EV) prices or excluding SMEs. The debate centered on market regulation versus industrial competitiveness, balancing regulation simplification with the demand for robust consumer incentives. Jorna’s commitment to the EU's 2050 net-zero target guided her responses, stressing value chain resilience.
The biotechnology policy debate focused on EU competitiveness and authorisation delays. Rainer Becker (DG SANTE) and Kristin Schreiber (DG GROW) outlined the need for regulatory streamlining via Biotech Act I and anticipated Biotech Act II, targeting strategic autonomy and value chain resilience. MEPs from the EPP called out long EFSA approval timelines, especially for novel proteins, urging faster procedures. Schreiber acknowledged public hesitancy and the need for supportive market conditions, noting bio-based innovation's current cost challenges.
The meeting produced concrete proposals such as the €1.5 billion Battery Booster fund with performance-based loans, binding deadlines for biotech approval procedures, and planned strategic reviews of hydrogen import corridors and infrastructure priorities. Conversely, some MEPs delivered more generalized critiques or calls for broader scopes and stronger consumer protections without detailed policy blueprints.
Stakeholders affected include EU regulatory bodies managing infrastructure and health approvals, national authorities balancing sovereignty with EU integration, automotive and biotech industries navigating regulation and market conditions, and EU consumers facing potential price impacts on EVs and biotech products. The Commission’s approach favors increased supranational coordination and strategic industrial support, potentially raising compliance and market access burdens but aiming to secure EU competitiveness and climate goals.
Looking ahead, ITRE’s subsequent sessions later in January 2026 and the Commission’s scheduled February call for evidence on biotech barriers signal ongoing scrutiny and refinement of these strategic sectors. Whether the Commission balances MEPs’ demands for more transparency, consumer affordability, and national input will be key to shaping the EU's integrated energy, automotive, and biotech policies.